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Abstract
Background Hilar cholangiocarcinoma is the most common
malignant tumor affecting the extrahepatic bile duct. Surgical
treatment offers the only possibility of cure, and it requires
removal of all tumoral tissues with adequate resection mar-
gins. The aims of this review are to summarize the findings
and to discuss the controversies on the extent of surgical
resection aiming at cure for hilar cholangiocarcinoma.
Methods The English medical literatures on hilar cholangio-
carcinoma were studied to review on the relevance of ade-
quate resection margins, routine caudate lobe resection, extent
of liver resection, and combined vascular resection on periop-
erative and long-term survival outcomes of patients with
resectable hilar cholangiocarcinoma.
Results Complete resection of tumor represents the most im-
portant prognostic factor of long-term survival for hilar chol-
angiocarcinoma. The primary aim of surgery is to achieve R0
resection. When R1 resection is shown intraoperatively, fur-
ther resection is recommended. Combined hepatic resection is
now generally accepted as a standard procedure even for
Bismuth type I/II tumors. Routine caudate lobe resection is
also advocated for cure. The extent of hepatic resection re-
mains controversial. Most surgeons recommendmajor hepatic
resection. However, minor hepatic resection has also been
advocated in most patients. The decision to carry out right-
or left-sided hepatectomy is made according to the
predominant site of the lesion. Portal vein resection should
be considered when its involvement by tumor is suspected.
Conclusion The curative treatment of hilar cholangiocarcino-
ma remains challenging. Advances in hepatobiliary tech-
niques have improved the perioperative and long-term surviv-
al outcomes of this tumor.
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Introduction
Hilar cholangiocarcinoma, or Klatskin tumor, is the most
common malignant tumor affecting the extrahepatic bile duct.
It is relatively slow growing and is usually small at clinical
presentation. Only a very few patients with unresectable,
indolent, and slow-growing hilar cholangiocarcinoma can
have long-term survival [1]. The prognosis of most patients
with unresectable tumor is poor because of the vital position of
the tumor, with a median survival of less than 1 year. The
treatment for hilar cholangiocarcinoma is challenging.
Surgical resection remains the only potentially curative thera-
py. The survival rates for patients who had received R1 or R2
resection were significantly better than those with
unresectable tumors [2–4]. In the old days, surgical treatment
of hilar cholangiocarcinoma aimed mainly at obtaining a
diagnosis through laparotomy and relieving obstructive jaun-
dice through surgical intubation or internal bypass [5]. In the
past three decades, the extent of surgical resection for hilar
cholangiocarcinoma has shifted from local excision of the
affected bile duct at the liver hilum with a local cone of
adjacent liver parenchyma to more extensive resections in-
volving combined major liver resection with increased long-
term survival rates and decreased mortality and morbidity
[6–10]. It is now widely accepted that resection of the bile
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duct cannot be accepted as a curative operation, and radical
resection with combined hepatectomy is now adopted bymost
surgeons. The key strategy of surgical resection is to achieve
adequate resection margins. This article focuses on the con-
troversies in radical surgical resection of hilar cholangiocarci-
noma, including issues about the relevance of adequate resec-
tion margins, routine caudate lobe resection, extent of liver
resection, and combined vascular resection on perioperative
and long-term survival outcomes of patients with resectable
hilar cholangiocarcinoma.
Materials and methods
English medical literatures were extensively searched via
online pubmed using the search strategy “hilar cholangiocar-
cinoma OR Klatskin tumor”. Studies focusing on curative
surgical resection for hilar cholangiocarcinoma were included.
Case report and studies with less than 40 resections were
excluded. Outcomes of surgical resection from 73 studies
published during the period 1990–2014 were extracted and
summarized in Table 1. Correlation was analyzed by




The most important factor affecting long-term survival in the
surgical treatment of hilar cholangiocarcinoma is whether the
tumor has been completely resected on histological examina-
tion (R0 resection). The margin status include R0 margin (no
residual tumor), R1 margin (microscopic residual tumor), and
R2 margin (macroscopic residual tumor). Patients with R1
margin or R2 margin have a dismal survival [11, 12]. Of the
many clinicopathological factors affecting long-term sur-
vivals, R0 resection is the only factor which can be modified
by the surgeon. Thus, the primary goal of surgical therapy is to
achieve R0 resection [13].
Several reports have suggested that the long-term survivals
after R0 and R1 were not significantly different [14–16].
There is a possibility that in these reports, some of the patients
with R1 resection were mistakenly classified as R0 resection
because there was no adequate sampling of the margins,
especially in patients with narrow resection margins. Endo
et al. classified their patients who have received R0 resection
into the wide margin group and the narrow margin group. Of
all the patients with R0 bile duct margins shown intraopera-
tively, only 60 % were associated with improvement in
disease-specific survival when compared with patients with
R1 resections. While the group of patients with wide margin
experienced better, the group of patients with narrow margin
had similar disease-specific survival similar to those patients
who underwent R1 resection [17]. Similarly, Seyama et al.
found that patients with surgical tumor-free margin of over
5 mm resulted in significantly better long-term survival than
those patients with a margin of less than 5 mm. However,
there was no difference between the survival of patients after
R0 resection with those who had a narrow margin (<5 mm) or
those who had received R1 resection [15]. The wider and the
longer the resection margin, the less likely it is to find a
positive resection margin [18]. Thus, wide and long R0 mar-
gins are required for resection with curative intent in hilar
cholangiocarcinoma resectional surgery.
It is frequently difficult to achieve a wide and long
resectional margin for curative treatment. First, hilar cholan-
giocarcinoma is located in the liver hilum surrounded by vital
structures. Second, it is difficult to determine the exact length
and width of microscopic tumor extension preoperatively and
intraoperatively. The biological nature of cholangiocarcinoma
involves proximal microscopic spread of the disease along the
bile duct extending beyond the palpable macroscopic bound-
aries of the primary hilar mass. Sakamoto et al. histologically
examined serial sections of 62 specimens of resected hilar
cholangiocarcinoma. They found that anastomotic recur-
rences never occurred in patients who had a proximal tumor-
free resection margin greater than 5 mm, suggesting that a
5 mm tumor-free margin was adequate for curative intent [19].
However, it has been demonstrated that the longitudinal extent
of tumor at the proximal border ranged from 0.6 to 18.8mm in
the submucosa layer [19], and that the width of the superficial
extension showed a wide distribution of 31–52 mm [18, 19].
Surgeons, thus, cannot be certain on the length and width of
the resection margins. Third, intraoperative frozen-section
examination of ductal margins has an accuracy, sensitivity,
and specificity of only 56.5, 75.0, and 46.7 %, respectively
[20].
Nonetheless, to achieve real R0 resection, transection of the
proximal bile duct above the macroscopic border of the pri-
mary tumor should be carried out as high as technically
feasible with careful consideration of the potential morbidity,
and resection of hilar cholangiocarcinoma combined with
major hepatectomy has the potential to provide wide and long
resection margins on the ipsilateral side of the combined liver
resection [17].
Further resection
The recent reported incidences of positive resection margins
in patients who had undergone surgical resection with curative
intent ranged from 64.6 to 88.2 % at high-volume centers [4,
10, 14, 21–23].When a positive resection margin is diagnosed
intraoperatively using frozen section examination, further re-
section is recommended if technically possible to
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Nimura et al. 1990 55 84 93 11 35 38 41 25 NA 82 83 NA
Gazzaniga et al. 1993 48 NA NA 23 79 NA 20 NA NA NA NA NA
Ogura et al. 1993 55 51 60 2 22 23 NA 9 2 51 96 69
Sugiura et al. 1993 83 57 100 8 NA 20 33 22 5 67 NA NA
Su et al. 1996 49 49 57 10 47 15 NA 2 NA 22 NA 61
Nakeeb et al. 1996 109 26 14 4 39 11 NA NA NA NA NA NA
Klempnauer et al. 1997 151 77 77 10 NA 28 NA 26 1 27 NA 82
Miyazaki et al. 1998 76 71 86 13 33 26 40 26 9 86 NA NA
Launois et al. 1999 40 80 75 13 25 13 NA 18 NA 23 43 78
Kosuge et al. 1999 65 52 88 9 37 33 NA 5 5 83 73 NA
Neuhaus et al. 1999 80 55 83 8 NA 22 37 29 NA 83 NA 83
Miyazaki et al. 1999 93 70 86 10 38 26 NA 26 9 86 NA NA
Todoroki et al. 2000 101 14 58 4 14 28 67 NA NA NA 89 70
Lee et al. 2000 111 78 100 6 48 22 NA 26 4 100 NA NA
Gerhards et al. 2000 112 14 29 18 65 NA NA 9 8 NA NA 53
Nimura et al. 2000 142 76 90 9 49 NA 26 30 NA NA NA NA
Jarnagin et al. 2001 80 78 78 10 64 27 30 11 NA 28 50 NA
Kawarada et al. 2002 87 64 75 2 28 26 NA NA NA 69 89 NA
Shimada et al. 2003 53 66 77 9 45 15–25 34 19 13 74 87 49
Seyama et al. 2003 58 64 100 0 43 40 46 16 NA 100 94 71
Kawasaki et al. 2003 79 68 96 1 14 22 40 6 3 87 75 78
Kondo et al. 2004 40 95 78 0 48 NA NA 25 25 78 93 53
Jitsma et al. 2004 42 65 100 12 45 22 45 17 10 57 NA NA
Rea et al. 2004 46 80 100 9 52 26 30 NA NA 39 NA 85
Ramesh et al. 2004 46 70 76 7 28 22 25 7 NA 76 36 52
Hemming et al. 2005 53 80 98 9 40 35 45 43 6 98 66 NA
Jarnagin et al. 2005 106 77 82 8 62 NA NA 9 NA 34 49 NA
Dinant et al. 2006 99 31 38 15 66 27 33 7 NA 15 NA 55
Sano et al. 2006 102 61 100 0 50 44 NA 22 5 100 92 NA
Hasegawa et al. 2007 49 78 90 2 47 40 NA 6 0 90 NA 84
Baton et al. 2007 59 68 100 5 42 20 28 8 2 100 NA NA
Hidalgo et al. 2008 44 45 93 7 59 28 45 45 9 77 90 NA
Konstadoulakis
et al.
2008 59 66 86 7 25 34 NA 24 NA 64 81 86
Endo et al. 2008 101 81 82 5 NA 31 NA 9 NA 36 NA NA
Murakami et al. 2009 42 74 86 7 52 30 NA NA NA 90 NA NA
Young et al. 2009 51 57 92 8 75 20 40 41 10 92 NA 92
Miyazaki et al. 2009 107 59 91 2 NA 28 33 23 3 NA NA 83
Chen et al. 2009 138 89 100 0 30 27–34 NA 33 NA 92 74 67
Hirano et al. 2009 146 87 88 3 44 36 NA 45 14 88 NA 62
Giuliante et al. 2010 43 77 93 7 53 36 NA NA 1 NA 29 NA
Ercolani et al. 2010 51 73 100 10 51 34 44 8 4 78 82 100
Rocha et al. 2010 60 80 78 5 35 NA 54 NA NA 48 57 NA
Gulik et al. 2010 99 31 38 10§ 68§ NA NA 18 NA 39 NA NA
Kobayashi et al. 2010 119 66 92 NA NA NA NA NA NA NA NA NA
Unno et al. 2010 125 63 95 8 49 35 45 34 3 100 NA 80
Igami et al. 2010 298 74 98 2 43 42 52 37 18 98 NA 88
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obtain complete tumor removal [11, 12, 24]. However, further
resection of the bile duct at the proximal side can be techni-
cally difficult due to encroachment onto vital structures and
adjacent liver parenchyma [2, 25, 26]. Not every patient with
R1 resection can be subjected to further resection [17, 25]. For
patient who can be further resected because of technically
feasibility or no radial tumoral invasion, 54 to 83 % can
achieve R0 resection [12, 14, 17, 25]. Unfortunately, the
clinical usefulness of further resection has not yet been
established, and it is still controversial whether further resec-
tion improves patients’ survival [12, 14, 17, 25].While several
reports have suggested that further resection did not contribute
to improvement in survival [14, 17] probably because of the
limited further length of less than 5 mm that could be resected
[25], Ribero and colleagues achieved good results in 15 sec-
ondary negative margins in 18 additional resections [12].
Unfortunately, they did not record the exact length of further
bile duct resection. However, they demonstrated that the sur-
vival of patients who had a secondary R0 resection was
similar to that of the primarily R0-resected patients, and they
were significantly better than those patients with R1 resection.
They also showed similar median survival to recurrence and
similar incidence of local site recurrence when patients with
R1 resection were compared with patients with R0 resection,
independent of whether further resection was carried out [12].




























Lee et al. 2010 302 71 89 2 NA 33 47 13 2 89 86 81
Gulik et al. 2011 41 92 85 7 NA NA NA 22 NA 78 NA 78
Saxena et al. 2011 42 64 100 2 45 24 NA 26 5 36 78 79
Chauhan et al. 2011 51 73 76 12 69 29 NA 6 NA 8 NA NA
Guglielmi et al. 2011 62 74 87 10 55 15 NA 16 3 76 NA NA
Hemming et al. 2011 95 84 100 5 34 43 50 44 5 100 NA 89
Neuhaus et al. 2011 100 NA 100 11–12 NA 43 NA NA NA NA NA 90
Otto et al. 2011 123 79 89 6 NA 26 NA 38 NA 89 77 91
Li et al. 2011 215 66 95 5 NA 30 41 16 6 NA 73 41
Ruys et al. 2012 57 75 88 NA NA 42 NA NA NA NA 60 NA
Cannon et al. 2012 59 63 83 5 39 NA 58 NA NA NA 54 NA
Cho et al. 2012 105 71 78 14 NA 34 50 8 NA 59 NA 81
Kow et al. 2012 127 89 97 2 6 30–66 NA NA NA 55 NA 100
Matsuo et al. 2012 157 76 82 8 59 32 36 10 NA 36 53 NA
Lee et al. 2012 162 77 81 1 NA 42 45 6 2 76 66 69
Cheng et al. 2012 171 78 100 3 26 14 17 13 3 80 61 100
de Jong et al. 2012 305 65 73 12 NA 20 25 17 NA NA NA 44
Nuzzo et al. 2012 440 77 85 9 37 26 32 8 2 67 NA 59
Nagino et al. 2012 574 77 97 5 57 33 NA 36 13 97 90 85
Song et al. 2013 230 77 78 4 NA 33 40 10 1 44 100 70
Dumitrascu et al. 2013 90 76 73 8 53 27 31 13 3 50 69 76
Farges et al. 2013 366 NA 100 11 69 NA NA 23 NA NA NA 78
Gomez 2014 57 74 86 14 60 40 NA 9 4 86 67 NA
Yu 2014 238 50 51 1 18 17 NA 11¶ 20 NA NA 86
Furusawa et al. 2014 144 74 99 1 73 NA NA 15 3 100 NA 78
Tamoto 2014 49 82 100 4 63 NA NA 73 NA 100 NA NA
*Data indicates percentage of resections in patients explored with curative intent
§ In the last period (1998–2003, n=29)
¶ Data indicates percentage of portal vein resections in R0 resections
PVR indicates portal vein resecion
AR artery resecion; CR caudate lobe resecion; NA data not available
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tumor-free margins wide and long enough for curative intent.
It is recommended that more extended resections with ade-
quate surgical margins should be carried out when technically
possible and when the patient has good functional reserves
[25]. To further address these issues, randomized controlled
studies with adequate patients are required, and the adequate
length of bile duct resection should be carefully defined to
provide more convincing data.
Hepatic resection
In the old days, hilar cholangiocarcinoma had been considered
to be unresectable and palliative decompression of the
obstructed biliary tract using bypass surgery or tube-
drainage was popularly employed. Surgical resections with
curative intent were later attempted to achieve better survival
[27–31]. Both local resection of bile duct and resection com-
bined with major hepatectomy were used. The surgical strat-
egy was made according to the location and involvement of
the tumor mass. When the tumor was small or localized, the
tumor was resected together with an adjacent cone of liver
parenchyma. If it infiltrated into the liver parenchyma, com-
bined major liver resection was carried out [24, 27, 32, 33].
In 1990, a review on 581 resections for hilar bile duct
cancer was published: 245 patients (42.2 %) received local
bile duct confluence resection while 224 (38.6 %) patients
received resection of the bile duct confluence combined with
major liver resection [34]. Tumor cells from hilar cholangio-
carcinoma are apt to infiltrate along the bile duct wall and
invade into the surrounding vital structures as well as the
adjacent liver parenchyma because the confluence of the bile
ducts has thin walls and it is strategically situated. Even as
early as the 1980s [7, 31, 34], surgeons started to hold the
view that hilar cholangiocarcinoma should be regarded more
as a regional than a local disease. As a consequence, an
increasing number of combined major liver resections were
performed [34]. However, there was no survival benefit at that
time using bile duct resection combined with major hepatec-
tomy when compared with local resection of a cone of adja-
cent liver parenchyma [33, 35]. The increase in 5-year surviv-
al rate from 6 % for local resection to 14 % for major liver
resections was almost completely offset by the increase in
postoperative mortality from 9 % for local resections to
17 % for major liver resections [34]. Also, the mean survival
time [34] as well as the R0 resection rate [33, 35] had hardly
been improved by the use of combined major liver resection.
Over the last two decades, complex and aggressive surgical
resections were made possible with acceptable morbidity and
mortality rates by major advances in patient selection, radio-
logic assessment, surgical techniques, and perioperative care
[21, 33, 36–41]. At the same time, there are more evidences to
support bile duct resection with an adjacent cone of liver
parenchyma cannot be accepted as an adequate curative
treatment, and combined major hepatic resection is associated
with improved survival [38, 39, 42–44]. The main aim of the
aggressive surgical approach is to obtain R0 resection.
Figure 1 shows that the percentage of hilar cholangiocarcino-
ma resected with combined major hepatic resection in surgical
series is positively correlated with the tumor-free resection
margin rate. Most reports coming from single center studies
indicated that there was a progressive increase in proportion of
patients submitted to combined major hepatic resection with
an increased R0 resection rate and improved survival over the
study period [3, 37, 45–50] (Table 2). Bile duct resection
combined with major hepatic resection has now been increas-
ingly accepted as a standard surgical treatment for hilar chol-
angiocarcinoma [51].
Is hepatic resection necessary for type I or II hilar
cholangiocarcinoma
Even though combined major hepatic resection is widely
accepted for Bismuth type III and IV hilar cholangiocarcino-
ma, whether it is necessary for type I or II tumor is still
controversial. A number of researchers consider that tumor
resection with an adjacent cone of liver parenchyma is suffi-
cient for patients with type I or II tumor [10, 52–55] especially
for type I tumors [10, 21, 56, 57]. Launois et al. performed
combined major hepatectomy depending on two factors: tu-
mor location and TNM classification [58]. They performed
local hilar resection mainly for Bismuth I or II tumors with Tis
and T1 lesions and the survival seemed better than that of
combined major hepatectomy which was done mainly for
Bismuth III or IV tumors, suggesting that local hilar resection
is sufficient if the tumor is Bismuth I or II [58]. Similarly,
Otani et al. compared local hilar resection for Bismuth type I
or II tumors with T2 or less lesions with combined major
hepatectomy for type III or IV tumors and found that similar
R0 resection rates as well as cumulative survivals were equal-
ly achieved in the two groups [59]. They concluded that local
hilar resection was indicated for papillary T1 or T2 tumors in
Fig. 1 Positive correlation of hepatic resection rates and tumor-free
margin achievement. Data were extracted from Table 1
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Bismuth type I or II tumor [59]. However, there are limited
data to assess the effectiveness of combined major hepatic
resection for type I or II tumor in these studies, and it is
difficult for a surgeon to get the precise information on the
tumor classification or the TNM staging preoperatively or
intraoperatively [60]. Ikeyama et al. compared survival in
patients with nodular and infiltrating hilar cholangiocarcino-
ma who tolerated right hemihepatectomy with survival in
patients who tolerated bile duct resection with or without
limited hepatic resection, and recommended that the surgical
approach to Bismuth type I and II hilar cholangiocarcinoma
should be determined according to preoperative cholangio-
graphic features. For nodular and infiltrating hilar cholangio-
carcinoma, right hepatectomy is essential for cure, for papil-
lary tumor local resection with or without limited hepatic
resection is adequate [48]. A more recent retrospective study,
which aimed to evaluate surgical outcomes of bile duct resec-
tion alone and combined major liver resection in 52 patients
with Bismuth type I and II hilar cholangiocarcinoma, revealed
that concomitant liver resection had a higher curability, lower
local recurrence rate, and better overall survival with a similar
postoperative morbidity and mortality [61]. In addition, the
authors found that cancer recurred in three patients out of the
six R0 resectional papillary tumors treated by bile duct resec-
tion alone [61]. It seems that concomitant liver resection
should be considered in all patients with Bismuth type I and
II hilar cholangiocarcinoma regardless of the tumor classifi-
cation. Several types of hepatic resections were performed in
that study, including left or right hepatectomy or volume-
preserving liver resection [61]. In our experience, central
hepatectomy resecting segment 5 and segment 4b/extended
4b resection is the primary choice for type I and II tumors [62].
This operation is adequate for both negative resection margins
and good exposure. Properly conducted prospective random-
ized controlled trials are needed to validate the treatment
strategy for type I and II hilar cholangiocarcinoma.
Routine caudate lobe resection
The caudate lobe is located deep in the liver between the
inferior vena cava and the hepatic hilum, thus isolation and
resection of the caudate lobe remain a challenge for surgeons.
The importance of tumor involvement of the caudate lobe in
the treatment of hilar cholangiocarcinoma had not been fully
recognized two decades ago. Some surgeons do not adopt a
strategy of routine caudate lobe resection even now [33, 35],
mainly due to the deep anatomical location of the caudate lobe
and the concern on postoperative insufficient remnant liver
parenchyma. The result was dismal. Bengmark et al.
employed major liver resections in 100 % of the 22 patients
with hilar cholangiocarcinoma from 1968 to 1984; however,
they did not emphasize the inclusion of caudate lobe resection
in the surgical procedure [7]. R0 resection was achieved just in
18.2 % of the patients [7].
The close anatomic relationship between the caudate lobe
and the hilar cholangiocarcinoma was well studied by
Mizumoto et al. in 1986 [63]. As hilar cholangiocarcinoma
has a high chance to invade the biliary branches or directly
infiltrate the parenchyma of the caudate lobe [38–40, 64],
routine caudate lobe resection should be carried out for
Table 2 Surgery outcomes according to the time period in several series from single centers
Authors Published year Time period Resections R0 (%) PH (%) Mortality (%) Morbidity (%) 5-year survival (%)
Gerhards et al. 2000 1983 −1987 42 5 36 19 66 NA
1988 −1992 45 13 9 20 73 NA
1993 −1997 25 32 52 12 52 NA
Kawarada et al. 2002 1976 −1993 62 55 65 2 31 20
1994 −2000 25 88 100 4 20 50
Dinant et al. 2006 1988 −1993 45 13 9 20 73 22
1993 −1998 25 32 52 12 52 35
1998 −2003 29 59 72 10 68 59
Gulik et al. 2010 1988 −1993 45 13 9 NA NA 20
1993 −1998 25 32 52 NA NA
1998 −2003 29 59 72 10 68 33
Nagino et al. 2012 1977 −1990 72 75 92 11 76 23
1991 −2000 116 93 10 80
2001 −2005 168 78 98 3 52 38
2006 −2010 218 99 1 43
Furusawa et al. 2014 1990 −2000 70 70 99 1.4 85.7 33
2001 −2012 74 78 100 0 61 35
NA indicates data not available
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curative treatment of hilar cholangiocarcinoma [63]. Better R0
resection rates and higher cumulative survival rates are
achieved by concomitant caudate lobe resection [9, 39, 49].
At present, caudate lobe resection is increasing carried out for
hilar cholangiocarcinoma all over the world [9, 45, 49, 65].
Table 1 shows that, for the period of 2006 to 2014, there were
3447 caudate lobe resections in 4577 patients with surgical
resection for hilar cholangiocarcinoma, which are significant-
ly higher than the percentage of caudate lobe resection carried
out from 1980 to 2005 (Fig. 2). Two retrospective studies
published in 2012 aimed primarily to assess the specific role
of routine caudate lobe resection for Bismuth type III/IV hilar
cholangiocarcinoma found total caudate lobectomy contribut-
ed to improvement in survival [22, 66]. The role of routine
caudate lobe resection in Bismuth type I/II tumors is still
uncertain.
Nimura et al. reported in 1990 that 98 % of caudate lobe
resections were histologically confirmed to be tumor positive
[64]. However, other authors reported that the caudate lobe
was involved in hilar cholangiocarcinoma in 32.4±7.1 %
(mean±standard deviation) [38, 39, 45, 62, 67, 68]. It is our
opinion that it should be routine as at least one third of patients
had the caudate lobe involved by hilar cholangiocarcinoma.
Major liver resection or minor liver resection
There are still controversies on the optimal extent of hepatic
resection to achieve a high percentage of R0 resection for hilar
cholangiocarcinoma.
Combined major liver resection represents an aggressive
surgical approach to remove a large volume of hepatic paren-
chyma, including the use of right trisectionectomy (Couinaud
segment 1, 4–8), right hemihepatectomy (S1, 5–8), left
trisectionectomy (S1–5, S8), or left hemihepatectomy (S1–
4). This approach has widely been advocated as a prime
choice of surgical treatment for hilar cholangiocarcinoma,
especially in patients with advanced tumors [69–71]. It is
believed that combined major liver resection has the advan-
tage to increase surgical curability by obtaining wide and
negative surgical resection margins [72, 73]. In addition,
hemihepatectomy/trisectionectomy is technically feasible
and can be carried out bymany surgeons. Themajor drawback
of combined major liver resection is the small postoperative
liver remnant which is associated with high surgical morbid-
ities and mortalities [44, 49, 74, 75]. Dinant et al. reported
hospital morbidity of 70.3 % (26/37) and mortality of 21.6 %
(8 dead in 37) in patients after hemi- or extended
hemihepatectomy [49]. Similarly, Ramesh et al. and
Gerhards et al. reported that the overall mortality rate was
25 % (3/12 and 8/32, respectively) after major liver resections
resulting in postoperative liver failure [50, 75]. Thus, the
increase in resectability rate can be offset by the increase in
postoperative mortality after associated major liver resection.
Some approaches have been proposed to reduce the perioper-
ative risk of associated major liver resection, including ade-
quate assessment of the volume/function of the future remnant
liver, preoperative biliary drainage, and portal vein emboliza-
tion (PVE). Kawasaki et al. showed an in-hospital mortality
rate as low as 1.3 % could be achieved after extended, mainly
right, hepatectomy with routine preoperative biliary drainage
and hemihepatic PVE [60]. Preoperative PVE is thought to be
effective to induce hypertrophy in the remnant liver and thus
may increase safety for patient who is considered insufficient
in remnant liver volume. However, the benefit of preoperative
biliary drainage and PVE has not been fully recognized and
consensus of indication criteria has not yet been established
[52, 60, 71, 76–78]. PVE procedure may delay the surgical
resection and associate with rapid tumor growth or liver
metastases. Besides, the estimated blood loss and operation
time were reported significantly higher in PVE group [52].
In the late twentieth century, Nimura and Miyazaki advo-
cated using minor central hepatic resection in carefully select-
ed patients to preserve as much as possible the functional liver
volume [44, 64]. Limited central liver resection means exci-
sion of liver segments/subsegments around the liver hilum,
such as segment 1 resection, segment 1 and 4 (4b) resection,
segment 1, 4 (4b), and 5 resection, or mesohepatectomy
(segment 1, 4 (4b), 5, and 8 resection). We believe that this
approach should take an important part in surgical treatment
for most of the hilar cholangiocarcinoma. First, a large amount
of liver parenchyma involved in combined major liver resec-
tion is free of tumor and it is not necessarily to resect these liver
tissues. Based on a three-dimensional perception of the tumor
located centrally in the liver, the aim of the curative resection is
to resect adequately the bile duct bifurcation with the adjacent
liver parenchyma. Generally, resection of segment 1, 4 (4b),
and 5 is adequate. The extent of liver resection can occasion-
ally be modified to include partial segment 6, 7, and 8 if
necessary (Fig. 3). Minor central liver resection can be per-
formed in patients with type I, type II, type IIIa, and type IIIb
Fig. 2 Caudate lobe resection rate according to the time period. Data
were extracted from Table 1
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tumors [62] and even for type IV tumors [56]. Second,
although there are some concerns that minor central liver
resectionmaydecrease the rate of curative surgical resection,
the Japanese surgeons have shown clearly that surgical cur-
ability and postoperative survival rates in selected patients
with minor central hepatic resection were not compromised
and surgicalmorbidity/mortality ratewas significantly lower
than that in the combinedmajor liver resection group [44, 79,
80]. Similarly, patients who received minor central liver
resection had good perioperative outcomes (9.7%morbidity
and 0 % mortality) with no decreased long-term survival
rates (5-year survival rates were 34 % for minor resection
vs. 27% formajor resection) [62].One should be noticed that
there is an intrinsic limitation in these retrospective studies.
Patients submitted in major or minor resection groups were
not randomized controlled. Select bias occurred when the
surgeons made the decision of surgical strategy. Minor re-
sections tend to be chosen for type I to III tumors or tumors
confined to the first-order hepatic duct. Thus, it is difficult to
tell the differences of these two surgical strategies in a tumor
with a certain bismuth type or T stage. More recently, a
technique of modified extended liver resection which aimed
to reduce the removal of the amount of functional liver
parenchyma has been described with a R0 resection rate of
92%and anoverallmortality rate of 7% [81]. In this strategy,
segment 4awaspreserved in extended right hepatectomyand
a modified extended left hepatectomy was performed by
preserving the bile duct of segment 8 with its associated
parenchyma on the cranial side. The authors also employed
mesohepatectomy as an alternative to extended right hepa-
tectomy for Bismuth type IIIa and IV tumors, when tumor
infiltration into the ducts of segments 6 and 7was limited and
the right hepatic artery was not involved [81]. Third, even
though minor central liver resection is technically more
difficult than theother types ofmajor liver resectionsbecause
of the many intrahepatic ductal openings that need to be
anastomosed, we have described a special technique of
hepaticojejunostomy to solve this problem [62].
The lack of consensus on the extent of liver resection seems
to arise mainly from the difficulty in precisely determining the
extent of the proximal tumor preoperatively and intraopera-
tively. Kawasaki et al. argued against minor central liver
resection and claimed that major hepatectomy should be
performed for all patients with hilar cholangiocarcinoma be-
cause of the limitations of the currently available preoperative
diagnostic modalities [60]. Some surgeons thought minor
central liver resection should be limited strictly to patients
with T2 tumor which has not invaded beyond any of the
segmental hepatic ducts [44, 50, 62, 80]. Central minor liver
resection carried out departing from these principles may
result in poor survival outcomes. Indeed, minor central liver
resections with curative intent should only be applied after
precise anatomical assessment of the biliary tract with ade-
quate assessment of the extent of tumor [44, 81]. The dilemma
between major liver resection with potential postoperative
liver failure and central minor liver resection with potential
positive resection margins might be solved by advances in
preoperative assessment. Concomitant use of three dimension
and multiplanar reconstruction images using multidetector
row computed tomography data can precisely detect both
longitudinal and vertical tumor invasion [82]. This technique
is noninvasive and can improve the curative resection rate,
which might reduce the risk of positive margin even in minor
liver resection. Sasaki et al. estimated length of proximal
hepatic ducts using this technique, and found 17 in 18 hepatic
ducts (94 %) were diagnosed negative [83]. However, this
technique has not yet been evaluated in minor liver resections
to our knowledge. Further advances in sensitivity of this
technique are expected andmay provide the hope to determine
the extent of surgical resection for a tumor in a patient.
Left- or right-sided hepatectomy
The decision of whether right- or left-sided hemihepatectomy
is indicated is made according to the predominant site of the
lesion. In general, right hemihepatectomy can be applied to
type IIIa tumors and IV tumors when the lesion is predomi-
nantly located in the right hepatic duct; whereas left
hemihepatectomy can be applied to type IIIb tumors and IV
tumors with left-sided predominance [60, 84, 85].
Right or extended right hemihepatectomy, the most radical
surgical procedure, is routinely adopted by many surgeons on
the basis of several anatomical considerations for patients with
centrally situated hilar cholangiocarcinoma which can be
treated by either combined right or left hemihepatectomy [8,
42, 51, 60, 86]. First, the extrahepatic part of the left hepatic
duct is longer than the right hepatic duct, and the distance from
the bifurcation to the sectional duct ramification is also much
longer in the left liver. Second, the hepatic duct confluence lies
on the right side of the hepatic hilum. Third, the right hepatic
artery generally runs behind the common hepatic duct, and it
is more likely to be invaded by tumor. Fourth, the left portal
vein is also longer than the right portal vein. Finally, there are
many anatomic variations which can jeopardize the safe per-
formance of left-sided hepatectomy [87]. Therefore, right-
sided hepatectomy is thought to be technically easier and
Fig. 3 Minor liver resection. Liver parenchyma adjacent to the liver
hilum, including segment 1, 4b, 5, and part of segment 6, 7, 8, is resected.
Resection of segment 4b and 5 provides good exposure
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has the additional advantage of radicality [42, 60, 88]. It is also
emphasized that right-sided hepatectomy has superiority be-
cause it enabled en-bloc resection of the hepatic ductal con-
fluence and its surrounding structures [89, 90]. In a right-sided
hepatectomy predominated study, extended left hepatectomy
was only occasionally performed as an alternative because of
insufficient remnant liver volume [60]. Recently, Neuhaus
et al. described the hilar en-bloc resection for hilar cholangio-
carcinoma which comprises of resecting en bloc the portal
vein bifurcation, the right hepatic artery, and liver segments 1
and 4 to 8, and showed its oncological superiority to the
conventional combined major hepatectomy [91].
The major drawback of the right-sided hepatectomy is loss
of a large volume of liver mass. Farges et al. reported a higher
mortality rate after right-sided hepatectomy than left-sided
hepatectomy [76]. Some surgeons also prefer left-sided hepa-
tectomy because segment 4, an anatomical part of the left liver
[81], is potentially invaded by tumor. By routinely resection
segment 4, left-sided hepatectomy preserves more liver pa-
renchyma than the right-sided approach (with only segment 2
and 3 remaining) [46].
Even though right-sided hepatectomy is the preferred ap-
proach for hilar cholangiocarcinoma [21], if there is a choice,
in some series, left- or right-sided hepatectomies were carried
out in a comparable number of patients [38, 52, 92]. In a
recently large series published by Nagino et al. on 574 pa-
tients, left-sided hepatectomy contributed more than right-
sided hepatectomy (51.8 vs. 38.3 %) [79]. In that cohort, type
IV tumor took 45.5% of all the cases and type III took 39.2%.
It seems that the author may prefer left-sided hepatectomy
even for type IV tumors.
Shimuzu et al. performed left-sided hepatectomy for
Bismuth type IIIb tumors in 88 patients and right-sided hep-
atectomy for type IIIa and IV tumors in 84 patients and
showed equivalent operative curability and postoperative
long-term survival between patients undergoing left-sided
hepatectomy and right-sided hepatectomy [88]. Similarly, in
a recent series reported by Lim et al., survival and recurrence
rates after left hepatectomy were not significantly different
from right hepatectomy in patients with type I and II hilar
Fig. 4 Portal vein resection rate significantly correlate with Bismuth
type. Data were extracted from Table 1
Table 3 Complications related to portal vein resection
Authors Published year Resections (n) PVR (n) Outcomes of PVR
Klempnauer et al. 1997 151 39 Three portal vein thrombosis
Neuhaus et al. 1999 80 23 Do not associate with mortality
Gerhards et al. 2000 112 10 Significant predictors of increased mortality.
Capussotti et al. 2002 36 5 Do not associate with morbidity and mortality
Kawasaki et al. 2003 79 5 Do not associate with survival
Seyama et al. 2003 58 9 Do not associate with survival
Dinant et al. 2006 99 7 Do not associate with morbidity and mortality
Hasegawa et al. 2007 49 3 Do not associate with survival
Konstadoulakis et al. 2008 59 14 Do not associate with morbidity and mortality
Yong et al. 2009 51 21 Zero mortality, and 1 portal vein thrombosis
Lee et al. 2010 302 40 Zero mortality, and 1 portal vein thrombosis
Igami et al. 2010 298 111 Five portal vein thrombosis
Hemming et al. 2011 95 42 Do not associated with mortality
Nagino et al. 2012 574 206 Do not associated with mortality
de Jong et al. 2012 305 51 Increase perioperative risk (mortality)
Song et al. 2013 230 22 One portal vein thrombosis
Gomez et al. 2014 57 5 One portal vein thrombosis
Yu et al. 2014 119 25 Had no effect on patient survival
Tamoto et al. 2014 49 36 Do not associate with post-operative complications.
PVR portal vein resection
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cholangiocarcinoma [61]. Further studies are required to iden-
tify the treatment strategy for type IV hilar cholangiocarcino-
ma between right- and left-sided hepatectomy.
Combined vascular resection
The anatomical location of hilar cholangiocarcinoma is close
to the portal vein bifurcation and the hepatic artery. These
vascular structures are often invaded by tumor. The involve-
ment of these vascular structures calls for combined vascular
resection to achieve R0 resection. The indications for com-
bined vascular resection include intraoperative suspicion of
gross tumor invasion to the vessels [43, 93, 94], tight adher-
ence of the tumor to the vessels during vascular
skeletonization [8, 22, 55] and routine resection of portal vein
in systematic radical surgery as advocated by some authors
[10]..
Concomitant hepatic arterial resection and reconstruction
should be performed with caution because it may result in
higher morbidity and mortality rates but without any proven
survival benefit [95]. Recent three meta-analyses draw similar
conclusions that portal vein resection does not affect on post-
operative mortality [95–97]. This consensus needs to be care-
fully interpreted. First, Wu et al. conducted the conclusion
from subgroup analysis including studies from experienced
surgeons and those published after 2007 [97]. Second, Abbas
et al. draw the conclusion in an indirect manner. They found
that the increase in mortality in patients who received vascular
resection resulted from concomitant hepatic arterial resection,
thus supposed that portal vein resection had no impact on
postoperative mortality [95]. Another similar conclusion from
these studies is that portal vein resection does not increase
morbidity [95–97], and there is only occasional postoperative
portal vein thrombosis (Table 3). Thus, portal vein resection
can be performed safely. However, patients in portal vein
resection cohort have lower 5-year survival rates. At first sight,
the value of portal vein resection is limit for hilar CC patients
with portal vein involvement. One should notice that patients
who received portal vein resection had significantly higher
rates of advanced disease (T3 and T4) when compared with
patients without portal vein involvement [10, 95, 97], and they
tended to have Bismuth III or IV tumors (Fig. 4). The impor-
tance of portal vein resection should be revealed by investigat-
ing the impact of portal vein resection on the surgical results
for patients with the same tumor stage and Bismuth type.
The histological involved margin status seems more im-
portant than the presence of direct invasion/involvement of
portal vein for long-term overall survival [10]. Even the role of
portal vein resection on R0 margin rates is still controversial
[95–97], logically portal vein resection allows patients who
had advanced tumor a chance to achieve a better histological
result. Therefore, when portal vein invasion is suspected,
combined portal vein resection should be carried out. This
conclusion is further supported by a recent international, mul-
ticenter, retrospective study on a large cohort of patients [10].
The reported rates of actual tumor invasion into the
resected vessels varied from 22 to 100 % [8, 10, 90, 93, 94,
98–100]. This indicate that it is difficult to determine the
actual status of vascular involvement preoperatively or intra-
operatively and that the indication of portal vein resection is
quite variety. Therefore, some Japanese surgeons advocated
routine portal vein resection for hilar cholangiocarcinoma to
achieve better long-term survival [4, 8, 91, 101]. However, the
benefit of routine portal vein resection requires further evi-
dence to support [5, 13, 95].
Conclusion
Treatment for hilar cholangiocarcinoma remains challenging.
In order to improve surgical outcomes for patients with hilar
cholangiocarcinoma, strategy of surgical resection with cura-
tive intent has improved over the years. Some consensuses
have been reached, including R0 margin achievement, routine
caudate lobe resection, combination of partial hepatectomy,
and portal vein resection when involved by tumor. However,
there are still several controversial issues need to be further
clarified. Improvement of hepatobiliary imageological tech-
nique that can provide more accurate information of the tumor
extent preoperatively will offer help. Due to the rarity of hilar
cholangiocarcinoma, prospective randomized studies can only
be carried out in multiple centers.
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